Comparing the two most used oral therapies for Multiple Sclerosis

By | December 22, 2016

“Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up,” co-authored by Thomas E. Love, Ph.D., the Center’s Director of Biostatistics and Evaluation, was named an Editor’s Choice by the journal Multiple Sclerosis and Related Disorders. The paper’s lead author is Carrie M. Hersh, of the Cleveland Clinic’s Lou Ruvo Center for Brain Health, in Las Vegas, and Dr. Hersh is a recent graduate of CWRU’s Clinical Research Scholars Program.

The authors present clinic-based data on efficacy and discontinuation rate of the two most used oral therapies for MS, fingolimod and dimethyl fumaric acid. Based on a large cohort of relapsing MS patients (>750) who received one of these agents, no difference in overall rate of discontinuation was seen but an earlier treatment discontinuation occurred with dimethyl fumaric acid. In addition, using robust analytical methods including propensity scores, the two therapies were associated with comparable clinical efficacy, overall brain MRI activity and discontinuation of treatment at 12 months.

The paper is available at this link.